Literature DB >> 7514774

Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats.

H Togashi1, M Matsumoto, M Yoshioka, M Hirokami, M Minami, H Saito.   

Abstract

The purpose of the present study was to evaluate stroke-prone spontaneously hypertensive rats (SHRSP) neurochemically by determining the cerebrospinal fluid (CSF) levels of acetylcholine (ACh), norepinephrine (NE) and serotonin (5-HT) as an index of central neuronal activity. The CSF ACh levels of 15- to 20-week-old SHRSP were significantly lower than those of age-matched Wistar Kyoto rats (WKY) both under the urethane/alpha-chloralose anesthesia and in freely moving conditions. The difference in the CSF ACh levels between SHRSP and WKY was more marked at 30-40 weeks. Sustained changes were not observed in the CSF NE and 5-HT levels. Thus, the progressive dysfunction in the central cholinergic system may characterize the pathophysiological state of this animal model with cerebral lesions caused by continuous high blood pressure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7514774     DOI: 10.1016/0304-3940(94)90854-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  14 in total

1.  Cognitive function and cholinergic transmission in patients with subcortical vascular dementia and microbleeds: a TMS study.

Authors:  Raffaele Nardone; Pierpaolo De Blasi; Martin Seidl; Yvonne Höller; Francesca Caleri; Frediano Tezzon; Gunther Ladurner; Stefan Golaszewski; Eugen Trinka
Journal:  J Neural Transm (Vienna)       Date:  2011-04-24       Impact factor: 3.575

2.  Dopamine differently modulates central cholinergic circuits in patients with Alzheimer disease and CADASIL.

Authors:  Raffaele Nardone; Yvonne Höller; Aljosha Thomschewski; Alexander Baden Kunz; Piergiorgio Lochner; Stefan Golaszewski; Eugen Trinka; Francesco Brigo
Journal:  J Neural Transm (Vienna)       Date:  2014-03-28       Impact factor: 3.575

Review 3.  Management of mixed dementia.

Authors:  Dina Zekry; Gabriel Gold
Journal:  Drugs Aging       Date:  2010-09-01       Impact factor: 3.923

Review 4.  Cholinesterase inhibitors and vascular dementia: another string to their bow?

Authors:  Roger Bullock
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 5.  Clinical pharmacokinetics of galantamine.

Authors:  Martin R Farlow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 6.  Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.

Authors:  Juan Wang; Hai-Yan Zhang; Xi-Can Tang
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

7.  Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.

Authors:  Gary Small; Timo Erkinjuntti; Alexander Kurz; Sean Lilienfeld
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 8.  Cholinergic dysfunction in vascular dementia.

Authors:  Gustavo C Román
Journal:  Curr Psychiatry Rep       Date:  2005-03       Impact factor: 8.081

Review 9.  Brain sites of movement disorder: genetic and environmental agents in neurodevelopmental perturbations.

Authors:  T Palomo; R J Beninger; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

Review 10.  Risk factors for vascular dementia: hypotension as a key point.

Authors:  Rita Moretti; Paola Torre; Rodolfo M Antonello; Davide Manganaro; Cristina Vilotti; Gilberto Pizzolato
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.